Skip to main content

Advertisement

SpringerLink
Log in

Fat, diabetes, and liver injury in chronic hepatitis C

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

It is increasingly recognized that host factors can modulate the fibrogenic response in patients with chronic hepatitis C. Obesity, because of its prevalence, and diabetes, which seems to occur more frequently in patients infected by the hepatitis C virus (HCV), are often present in patients with chronic hepatitis C. Both conditions result in fatty liver, which in turn is associated with more severe liver damage, especially fibrosis or inflammation. Steatosis can either originate from associated metabolic alterations (insulin resistance resulting in metabolic steatosis) or from a direct cytopathic effect of the virus (genotype 3, resulting in viral steatosis). Metabolic steatosis seems to be a factor in resistance to antiviral therapy, whereas viral steatosis is reduced in sustained responders. Whether metabolic steatosis has a direct role in liver fibrosis progression or is only a surrogate marker of an underlying defect triggering fibrogenesis, such as insulin resistance, is a subject of debate. High serum glucose levels and diabetes have a strong and independent profibrogenic impact. Exciting new data are expanding our understanding of the mechanisms of steatogenesis in HCV infection and providing potential links between insulin resistance or hyperglycemic states and liver fibrogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76–79.

    Article  PubMed  Google Scholar 

  2. Mehta SH, Brancati FL, Sulkowski MS, et al.: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000, 133:592–599. Important study documenting the association between chronic hepatitis C and diabetes in the general population.

    PubMed  CAS  Google Scholar 

  3. Mehta SH, Brancati FL, Strathdee SA, et al.: Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50–56. Demonstrates that hepatitis C precedes the development of diabetes and not the opposite.

    Article  PubMed  Google Scholar 

  4. Allison ME, Wreghitt T, Palmer CR, Alexander GJ: Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994, 21:1135–1139.

    Article  PubMed  CAS  Google Scholar 

  5. Caronia S, Taylor K, Pagliaro L, et al.: Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 30:1059–1063.

    Article  PubMed  CAS  Google Scholar 

  6. Fraser GM, Harman I, Meller N, et al.: Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996, 32:526–530.

    PubMed  CAS  Google Scholar 

  7. Grimbert S, Valensi P, Levy-Marchal C, et al.: High prevalence of diabetes mellitus in patients with chronic hepatitis C: a case-control study. Gastroenterol Clin Biol 1996, 20:544–548.

    PubMed  CAS  Google Scholar 

  8. Knobler H, Schihmanter R, Zifroni A, et al.: Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000, 75:355–359.

    PubMed  CAS  Google Scholar 

  9. Konrad T, Zeuzem S, Toffolo G, et al.: Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection. Digestion 2000, 62:52–59.

    Article  PubMed  CAS  Google Scholar 

  10. Mason AL, Lau JY, Hoang N, et al.: Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 29:328–333.

    Article  PubMed  CAS  Google Scholar 

  11. Ozyilkan E, Arslan M: Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1996, 91:1480–1481.

    PubMed  CAS  Google Scholar 

  12. Petit J-M, Bour J-B, Galland-Jos C, et al.: Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001, 35:279–283. Suggests that insulin resistance develops with progressive liver injury, particularly fibrosis, before the cirrhotic stage.

    Article  PubMed  CAS  Google Scholar 

  13. Zein NN, Abdulkarim AS, Wiesner RH, et al.: Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000, 32:209–217.

    Article  PubMed  CAS  Google Scholar 

  14. Gray H, Wreghitt T, Stratton IM, et al.: High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 1995, 12:244–249.

    Article  PubMed  CAS  Google Scholar 

  15. Simo R, Hernandez C, Genesca J, et al.: High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996, 19:998–1000.

    Article  PubMed  CAS  Google Scholar 

  16. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, et al.:High prevalence of diabetes mellitus among adult betathalassaemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1999, 11:1033–1036.

    Article  PubMed  CAS  Google Scholar 

  17. Petrides AS, Vogt C, Schulze-Berge D, et al.: Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994, 19:616–627.

    Article  PubMed  CAS  Google Scholar 

  18. Dienes HP, Popper H, Arnold W, Lobeck H: Histologic observations in human hepatitis non-A, non-B. Hepatology 1982, 2:562–571.

    Article  PubMed  CAS  Google Scholar 

  19. Scheuer PJ, Ashrafzadeh P, Sherlock S, et al.: The pathology of hepatitis C. Hepatology 1992, 15:567–571.

    Article  PubMed  CAS  Google Scholar 

  20. Czaja A, Carpenter H, Santrach P, Moore S: Host- and diseasespecific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998, 29:198–206.

    Article  PubMed  CAS  Google Scholar 

  21. Bach N, Thung SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992, 15:572–577.

    Article  PubMed  CAS  Google Scholar 

  22. Fiore G, Fera G, Napoli N, et al.: Liver steatosis and chronic hepatitis C: a spurious association? Eur J Gastroenterol Hepatol 1996, 8:125–129.

    Article  PubMed  CAS  Google Scholar 

  23. Hwang SJ, Luo JC, Chu CW, et al.: Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001, 16:190–195.

    Article  PubMed  CAS  Google Scholar 

  24. Gordon SC, Elloway RS, Long JC, Dmuchowski CF: The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993, 18:1338–1343.

    Article  PubMed  CAS  Google Scholar 

  25. Delladetsima JK, Rassidakis G, Tassopoulos NC, et al.: Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol 1996, 24:27–32.

    Article  PubMed  CAS  Google Scholar 

  26. Poynard T, Ratziu V, McHutchison J, et al.: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75–85. Largest study to document the impact of treatment on steatosis in chronic hepatitis C.

    Article  PubMed  CAS  Google Scholar 

  27. Rubbia-Brandt L, Quadri R, Abid K, et al.: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000, 33:106–115.

    Article  PubMed  CAS  Google Scholar 

  28. Serfaty L, Andreani T, Giral P, et al.: Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001, 34:428–34. Important study documenting the interaction between HCV infection and altered lipid metabolism.

    Article  PubMed  CAS  Google Scholar 

  29. Mihm S, Fayyazi A, Hartmann H, Ramadori G: Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997, 25:735–739. First demonstration that genotype 3 is specifically associated with steatosis.

    Article  PubMed  CAS  Google Scholar 

  30. Adinolfi LE, Gambardella M, Andreana A, et al.: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358–1364. Important study introducing the distinction between viral and metabolic steatosis.

    Article  PubMed  CAS  Google Scholar 

  31. Rubbia-Brandt L, Giostra E, Mentha G, et al.: Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001, 35:307.

    Article  PubMed  CAS  Google Scholar 

  32. Kumar D, Farrell GC, Fung C, George J: Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002, 36:1266–1272.

    Article  PubMed  Google Scholar 

  33. Westin J, Nordlinder H, Lagging M, et al.: Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002, 37:837–842.

    Article  PubMed  Google Scholar 

  34. Moriya K, Yotsuyanagi H, Shintani Y, et al.: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997, 78:1527–1531. First demonstration that steatosis could be a cytopathic effect induced by the core protein of HCV.

    PubMed  CAS  Google Scholar 

  35. Moriya K, Fujie H, Shintani Y, et al.: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065–1067.

    Article  PubMed  CAS  Google Scholar 

  36. Perlemuter G, Sabile A, Letteron P, et al.: Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Faseb J 2002, 16:185–194. In vitro and in vivo demonstration of the alteration of lipid secretion by HCV core protein.

    Article  PubMed  CAS  Google Scholar 

  37. Lerat H, Honda M, Beard MR, et al.: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122:352–365.

    Article  PubMed  CAS  Google Scholar 

  38. Fujie H, Yotsuyanagi H, Moriya K, et al.: Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999, 59:141–145.

    Article  PubMed  CAS  Google Scholar 

  39. Barba G, Harper F, Harada T, et al.: Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997, 94:1200–1205. First demonstration of the in vitro physical interaction between a structural HCV protein and intracellular lipids.

    Article  PubMed  CAS  Google Scholar 

  40. Okuda M, Li K, Beard MR, et al.: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366–375. Demonstrates mitochondrial damage and reactive oxygen species production by HCV core protein.

    Article  PubMed  CAS  Google Scholar 

  41. Kawamura T, Furusaka A, Koziel MJ, et al.: Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 1997, 25:1014–1021.

    Article  PubMed  CAS  Google Scholar 

  42. Pasquinelli C, Shoenberger JM, Chung J, et al.: Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997, 25:719–727.

    Article  PubMed  CAS  Google Scholar 

  43. Negro F: Hepatitis C virus and liver steatosis: Is it the virus? Yes it is, but not always. Hepatology 2002, 36:1050–1052. Smart editorial.

    Article  PubMed  Google Scholar 

  44. Thomssen R, Bonk S, Propfe C, et al.: Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992, 181:293–300.

    Article  CAS  Google Scholar 

  45. Sabile A, Perlemuter G, Bono F, et al.: Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 1999, 30:1064–1076.

    Article  PubMed  CAS  Google Scholar 

  46. Wong VS, Wight DG, Palmer CR, Alexander GJ: Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model. J Clin Pathol 1996, 49:465–469.

    PubMed  CAS  Google Scholar 

  47. Ong JP, Younossi ZM, Speer C, et al.: Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001, 21:266–271.

    Article  PubMed  CAS  Google Scholar 

  48. Castera L, Hezode C, Roudot-Thoraval F, et al.: Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003, 52:288–292.

    Article  PubMed  CAS  Google Scholar 

  49. Ratziu V, Saboury M, Poynard T: Worsening of steatosis and fibrosis progression. Gut 2003, 52:1386–1387.

    Article  PubMed  CAS  Google Scholar 

  50. Ratziu V, Munteanu M, Charlotte F, et al., for the O Study group:Profibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003, 39:1049–1055. Demonstrates the independent contribution of high serum glucose to different stages of fibrogenesis.

    Article  PubMed  CAS  Google Scholar 

  51. Ohata K, Hamasaki K, Toriyama K, et al.: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036–3043.

    Article  PubMed  Google Scholar 

  52. Monto A, Alonzo J, Watson JJ, et al.: Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002, 36:729–736.

    Article  PubMed  Google Scholar 

  53. Ortiz V, Berenguer M, Rayon JM, et al.: Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002, 97:2408–2414.

    Article  PubMed  Google Scholar 

  54. Hourigan LF, MacDonald GE, Purdie D, et al.: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999, 29:1215–1219. First attempt to determine the role of obesity as a cofactor of fibrosis in chronic hepatitis C.

    Article  PubMed  CAS  Google Scholar 

  55. McCullough AJ, Falck-Ytter Y: Body composition and hepatic steatosis as precursors for fibrotic liver disease. Hepatology 1999, 29:1328–1330. Smart editorial.

    Article  PubMed  CAS  Google Scholar 

  56. Clouston AD, Jonsson JR, Purdie DM, et al.: Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001, 34:314–320.

    Article  PubMed  CAS  Google Scholar 

  57. Hickman IJ, Clouston AD, Macdonald GA, et al.: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51:89–94. Preliminary but potentially valuable data on weight reduction as an adjuvant therapy in chronic hepatitis C.

    Article  PubMed  CAS  Google Scholar 

  58. Marfella R, Quagliaro L, Nappo F, et al.: Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001, 108:635–636.

    Article  PubMed  CAS  Google Scholar 

  59. Kashiwagi A, Asahina T, Nishio Y, et al.: Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes 1996, 45:S84-S86.

    PubMed  CAS  Google Scholar 

  60. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787–790.

    Article  PubMed  CAS  Google Scholar 

  61. Igarashi M, Wakasaki H, Takahara N, et al.: Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999, 103:185–195.

    PubMed  CAS  Google Scholar 

  62. Guha M, Bai W, Nadler JL, Natarajan R: Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000, 275:17728–17739.

    Article  PubMed  CAS  Google Scholar 

  63. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest 1989, 83:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  64. Wolff SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991, 10:339–352.

    Article  PubMed  CAS  Google Scholar 

  65. Bierhaus A, Chevion S, Chevion M, et al.: Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997, 46:1481–1490.

    Article  PubMed  CAS  Google Scholar 

  66. Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM: Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 2001, 34:943–952. First link between hepatic stellate cells and hyperglycemiainduced fibrosis.

    Article  PubMed  CAS  Google Scholar 

  67. Paradis V, Dargere D, Vidaud M, et al.: Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999, 30:968–976.

    Article  PubMed  CAS  Google Scholar 

  68. Williams EJ, Gaca MD, Brigstock DR, et al.: Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000, 32:754–761.

    Article  PubMed  CAS  Google Scholar 

  69. Letteron P, Fromenty B, Terris B, et al.: Acute and chronic hepatic steatosis lead to in vivo lipid peroxydation in mice. J Hepatol 1996, 24:200–208.

    Article  PubMed  CAS  Google Scholar 

  70. Reeves HL, Burt AD, Wood S, Day CP: Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996, 25:677–683.

    Article  PubMed  CAS  Google Scholar 

  71. Ikejima K, Honda H, Yoshikawa M, et al.: Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001, 34:288–297. Demonstration that leptin is necessary for fibrosis development.

    Article  PubMed  CAS  Google Scholar 

  72. Saxena NK, Ikeda K, Rockey DC, et al.: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002, 35:762–71.

    Article  PubMed  CAS  Google Scholar 

  73. Honda H, Ikejima K, Hirose M, et al.: Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002, 36:12–21.

    Article  PubMed  CAS  Google Scholar 

  74. Chitturi S, Farrell G, Frost L, et al.: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002, 36:403–409.

    Article  PubMed  CAS  Google Scholar 

  75. Kim JK, Kim YJ, Fillmore JJ, et al.: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001, 108:437–46.

    Article  PubMed  CAS  Google Scholar 

  76. Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673–1677. Demonstration of common pathways between insulin resistance and tissue inflammation.

    Article  PubMed  CAS  Google Scholar 

  77. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.

    Article  PubMed  CAS  Google Scholar 

  78. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.

    Article  PubMed  CAS  Google Scholar 

  79. Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639–644.

    Article  PubMed  CAS  Google Scholar 

  80. McCullough AJ: Obesity and its nurturing effect on hepatitis C. Hepatology 2003, 38:557–559. Smart editorial.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’h’epatogastroenterologie, Groupe Hospitalier Pitièalpêtrière, Paris, France

    Vlad Ratziu MD, JB, Jean-Baptiste Trabut MD & Thierry Poynard MD, PhD

Authors
  1. Vlad Ratziu MD, JB
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Baptiste Trabut MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thierry Poynard MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ratziu, V., Trabut, JB. & Poynard, T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 6, 22–29 (2004). https://doi.org/10.1007/s11894-004-0022-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-004-0022-5

Keywords

Search

Navigation